Drug Profile
Research programme: iminosugar antivirals - United Therapeutics
Alternative Names: EBI 001; Glycobiology antiviral agents; Iminosugar antivirals - United TherapeuticsLatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Synergy Pharmaceuticals; University of Oxford
- Developer Emergent BioSolutions
- Class Antivirals; Imino sugars; Small molecules
- Mechanism of Action Glucosidase inhibitors; Hepatitis B virus replication inhibitors; Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza virus infections
- Discontinued Encephalitis virus infections; Hepatitis B
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (PO)
- 04 Jun 2018 Discontinued - Preclinical for Encephalitis virus infections in USA (PO)
- 04 Jun 2018 Discontinued - Preclinical for Hepatitis B in USA (PO)